Alert-HF: Early Detection and Intervention on Atrial Fibrillation in Heart Failure Patients (Alert-HF)
The goal of this clinical trial is to learn if using remote heart rhythm monitoring strategies can reduce unplanned cardiac care utilization and improve health-related quality of life in adults with heart failure (HF). It focuses on adults with heart failure who have no history of an irregular heartbeat called atrial fibrillation (AF) and do not have an existing pacemaker or implantable defibrillator.
The main questions the trial aims to answer are:
- Does a continuous rhythm monitor placed under the skin or a patient-driven portable home device decrease unplanned cardiac care utilization?
- Do these rhythm monitoring strategies influence therapeutic management?
- Do these rhythm monitoring strategies improve patient-reported quality of life and overall survival?
Researchers will compare two monitoring groups to a standard care group over an 18-month period to see which approach works best in heart failure treatment
Participants will:
- either have a small heart monitor placed under their chest skin for heart rhythm observation (arm 1), use a handheld device to take regular heart recordings at home (arm 2) or follow standard care (arm 3) for a period of 18 months
- Answer a health survey at the start of the study and after 18 months of follow-up.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Dr. Schuuring, MD PhD
- Número de telefone: 0031534872000
- E-mail: mark.schuuring@utwente.nl
Locais de estudo
-
-
-
Enschede, Holanda, 7512 KZ
- Medisch Spectrum Twente
-
Contato:
- Dr Schuuring, MD PhD
- Número de telefone: 0031534872000
- E-mail: mark.schuuring@utwente.nl
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adult patients with HF and no history of documented AF on electrocardiogram (ECG)
Exclusion Criteria:
- Patients with CIED, such as an implantable cardioverter defibrillator (ICD), Cardiac Resynchronization Therapy Defibrillator (CRT-D), or pacemaker.
- Documented AF before inclusion
- Admission to hospices or palliative care
- Inability to communicate in Dutch or English.
- Participant under the age of 18 years old
- Participant is pregnant
- Mental disorders that, according to the treating physician, make participation unsafe
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Arm 1: Hospital-driven continuous monitoring with an implantable loop recorder
Arm 1: Hospital-driven continuous rhythm monitoring with an implantable loop recorder (ILR) placed subcutaneously in the left pectoral region. |
Hospital-driven continuous monitoring with an implantable loop recorder |
|
Comparador Ativo: Arm 2: Patient-driven portable ECG monitoring
Patient-driven single-lead portable ECG monitoring in which patients are instructed to send ECG recordings of at least 30 seconds both on a scheduled routine basis and whenever experiencing symptoms suggestive of an arrhytmia. |
Patient-driven portable ECG monitoring |
|
Comparador Ativo: Arm 3: Usual Care
All patients are treated according to the ESC guidelines (ESC HF 2026). This includes periodic outpatient utilization. |
Usual care |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of unplanned cardiac care utilization
Prazo: 18 months
|
Unplanned cardiac healthcare utilization will be assessed through systematic review of patients' medical records. The number of healthcare episodes occurring during the study observation period will be recorded. Each unique healthcare episode will be classified according to the principal setting of care: outpatient clinic, daycare/day-case admission, emergency care without admission, or hospitalization. Both total and stratified care utilization will be reported. An episode will be considered unplanned when healthcare is initiated in response to an acute, unexpected, worsening, or urgent cardiac health problem. Healthcare episodes involving transfers between care settings as part of the same continuous episode will be counted once and classified according to the highest level of care reached, to avoid double counting. |
18 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of planned cardiac care utilization
Prazo: 18 months
|
Planned healthcare utilization comprises healthcare episodes scheduled or arranged in advance for routine, preventive, diagnostic, therapeutic, monitoring, rehabilitation, or follow-up care. This includes planned hospitalizations, planned daycare/day-case encounters, and planned outpatient clinic visits. |
18 months
|
|
Time from inclusion to first diagnosis of AF
Prazo: 18 months
|
The clinical diagnosis of AF by a healthcare professional must be supported by ECG documentation demonstrating AF on a single-lead recording of at least 30 seconds or a standard 12-lead ECG, obtained using the assigned monitoring device or as part of routine clinical care. |
18 months
|
|
The number of participants diagnosed with AF according to the electronic health rercords (EHR)
Prazo: 18 months
|
AF diagnosis will be established based on electrocardiographic (ECG) documentation obtained either through the assigned monitoring strategy or as part of routine clinical care, as assessed by a qualified healthcare professional. |
18 months
|
|
Number of AF-related pharmacological and non-pharmacological management changes
Prazo: 18 months
|
Pharmacological changes include initiation, discontinuation, dose increase, dose decrease or switching of oral anticoagulants (OAC) and rate- and/or rhythm-control medications, including antiarrhythmic drugs. Non-pharmacological interventions include electrical or pharmacological cardioversion, catheter ablation and AF-related CIED implantation or reprogramming. The number of management changes will be grouped according to the treatment type and type of adjustment. |
18 months
|
|
Number of HF-related pharmacological and non-pharmacological management changes during the study observation period.
Prazo: 18 months
|
Pharmacological changes include initiation, discontinuation, dose increase, dose decrease or switching of guideline-directed medical therapy (GDMT), including ARNI/ACEi/ARB, beta-blockers, mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i) and diuretics. Non-pharmacological interventions include HF-related CIED implantation or device reprogramming. The number of management changes will be grouped according to the treatment type and type of adjustment. |
18 months
|
|
Number of overall arrhythmia diagnosis extracted from EHR
Prazo: 18 months
|
Number of overall arrhythmia diagnosis |
18 months
|
|
Changes in Quality of life from baseline to 18 months follow-up as assessed by the Quality of life Kansas City Cardiomyopathy Questionnaire
Prazo: 18 months
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) will be collected at baseline and 18 months. The scores are represented on a scale from 0 to 100 points, where lower scores represent more severe symptoms and higher scores less or no symptoms. |
18 months
|
|
Change in heart failure-related quality of life from baseline to 18-month follow-up, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ).
Prazo: 18 months
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) will be collected at baseline and 18 months. The scores are represented on a scale from 0 to 100 points, where lower scores represent more severe symptoms and higher scores less or no symptoms. |
18 months
|
|
Changes in overall Quality of Life from baseline to 18 months follow-up as assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L)
Prazo: 18 months
|
The EQ-5D-5L is a standardized questionnaire assessing health-related quality of life across five dimensions on a score from 1 to 5, with one no problems to a score of five with extreme problems on that domain. This allows for direct comparison between baseline and follow-up. The questionnaire also includes a visual analogue scale (EQ-VAS), ranging from 0 (worst imaginable health) to 100 (best imaginable health), on which participants rate their overall health. Furthermore, responses are used to calculate a health utility index score with values between 0 and 1. 0 indicates life valuation equal to death and one full health. |
18 months
|
|
Mortality
Prazo: 18 months
|
Mortality |
18 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicações e links úteis
Publicações Gerais
- Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, Ellinor PT, Cheng S, Vasan RS, Lee DS, Wang TJ, Levy D, Benjamin EJ, Ho JE. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation. 2016 Feb 2;133(5):484-92. doi: 10.1161/CIRCULATIONAHA.115.018614. Epub 2016 Jan 8.
- Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. doi: 10.1093/cvr/cvac013.
- Bhatnagar R, Fonarow GC, Heidenreich PA, Ziaeian B. Expenditure on Heart Failure in the United States: The Medical Expenditure Panel Survey 2009-2018. JACC Heart Fail. 2022 Aug;10(8):571-580. doi: 10.1016/j.jchf.2022.05.006. Epub 2022 Jul 6.
- Kober L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, Brugts JJ, Chioncel O, Donal E, Ferdinandy P, Jhund PS, Leyva F, Lorusso R, Madigan M, Mullens W, Paolillo S, Ryan N, Simpson M, Thiele H, Thune JJ, Van Craenenbroeck EM, Van Laake LW, Verbakel M; ESC Guidelines Advisory Group. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026 Aug 28:ehag100. doi: 10.1093/eurheartj/ehag100. Online ahead of print. No abstract available.
- Baez-Ferrer N, Rodriguez-Cabrera CM, Parra-Esquivel PC, Burillo-Putze G, Dominguez-Rodriguez A. Prognostic Impact of Hospital Discharge After Heart Failure Admission Without Structured Heart Failure Follow-Up. J Clin Med. 2024 Dec 13;13(24):7589. doi: 10.3390/jcm13247589.
- Kwok CS, Seferovic PM, Van Spall HG, Helliwell T, Clarson L, Lawson C, Kontopantelis E, Patwala A, Duckett S, Fung E, Mallen CD, Mamas MA. Early Unplanned Readmissions After Admission to Hospital With Heart Failure. Am J Cardiol. 2019 Sep 1;124(5):736-745. doi: 10.1016/j.amjcard.2019.05.053. Epub 2019 Jun 6.
- Jansen C, Otterspoor LC, van Pol PEJ, IJff GC, Sinkeler SJ, van den Heuvel M, Jansen MEP, Scholten M, van Zutphen K, Verstappen CCAG, Hermanides N, Joosen IA, Heinen S, Valk JG, Vollenbroek-Hutten MMR, Schuuring MJ, van Hout GPJ. Structuring telemonitoring in heart failure care in The Netherlands: design and operational protocol of a nationwide initiative. Eur Heart J Digit Health. 2025 Nov 5;7(2):ztaf130. doi: 10.1093/ehjdh/ztaf130. eCollection 2026 Mar.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- Alert-HF
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .